Dicot Pharma AB (STO:DICOT)

Market Cap	445.67M -67.0%
Revenue (ttm)	n/a
Net Income	-72.14M
EPS	-0.04
Shares Out	2.01B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	28,925,422
Open	0.2326
Previous Close	0.2332
Day's Range	0.2004 - 0.2400
52-Week Range	0.1851 - 1.1800
Beta	0.89
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Dicot Pharma AB

Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2015
• Employees: 4
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DICOT

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 22, 2026

Data Sources Report a data error